Paediatric heart transplantation recipients ≥7 years of age receiving donors with pre-existing coronary atherosclerosis showed progressive coronary artery disease

2021 ◽  
pp. 1-8
Author(s):  
Mi Jin Kim ◽  
Jeong Jin Yu ◽  
Seulgi Cha ◽  
Jae Suk Baek ◽  
Eun Seok Choi ◽  
...  

Abstract Background: This study aimed to determine the effect of donor-transmitted atherosclerosis on the late aggravation of cardiac allograft vasculopathy in paediatric heart recipients aged ≥7 years. Methods: In total, 48 patients were included and 23 had donor-transmitted atherosclerosis (baseline maximal intimal thickness of >0.5 mm on intravascular ultrasonography). Logistic regression analyses were performed to identify risk factors for donor-transmitted atherosclerosis. Rates of survival free from the late aggravation of cardiac allograft vasculopathy (new or worsening cardiac allograft vasculopathy on following angiograms, starting 1 year after transplantation) in each patient group were estimated using the Kaplan–Meier method and compared using the log-rank test. The effect of the results of intravascular ultrasonography at 1 year after transplantation on the late aggravation of cardiac allograft vasculopathy, correcting for possible covariates including donor-transmitted atherosclerosis, was examined using the Cox proportional hazards model. Results: The mean follow-up duration after transplantation was 5.97 ± 3.58 years. The log-rank test showed that patients with donor-transmitted atherosclerosis had worse survival outcomes than those without (p = 0.008). Per the multivariate model considering the difference of maximal intimal thickness between baseline and 1 year following transplantation (hazard ratio, 22.985; 95% confidence interval, 1.948–271.250; p = 0.013), donor-transmitted atherosclerosis was a significant covariate (hazard ratio, 4.013; 95% confidence interval, 1.047–15.376; p = 0.043). Conclusion: Paediatric heart transplantation recipients with donor-transmitted atherosclerosis aged ≥7 years had worse late cardiac allograft vasculopathy aggravation-free survival outcomes.

Author(s):  
A. О. Shevchenko

Statins should be used as a part of standard therapy in patients after heart transplantation. The effectiveness of statins is associated not only with their hypolipidemic action, but also with their immunomodulatory and antineoplastic properties. Statin therapy initiated early after heart transplantation improves the shortand long-term prognosis and outcomes, leading to a reduction in the incidence of cardiac allograft vasculopathy, acute rejection, and cancer. 


2013 ◽  
Vol 61 (10) ◽  
pp. E798 ◽  
Author(s):  
Alistair Aaronson ◽  
Michelle Kittleson ◽  
Jignesh Patel ◽  
Matthew Rafiei ◽  
Ashley Osborne ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document